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Background: In attempting to achieve optimal metabolic control, the day-to-day management is challenging for a
child with type 1 diabetes (T1D) and his family and can have a major negative impact on their quality of life. Augmenting
an insulin pump with glucose sensor information leads to improved outcomes: decreased haemoglobin A1c levels,
increased time in glucose target and less hypoglycaemia. Fear of nocturnal hypoglycaemia remains pervasive amongst
parents, leading to chronic sleep interruption and lack of sleep for the parents and their children.
The QUEST study, an open-label, single-centre randomized crossover study, aims to evaluate the impact on time in target,
in hypoglycaemia and hyperglycaemia and the effect on sleep and quality of life in children with T1D, comparing
a sensor-augmented pump (SAP) with predictive low glucose suspend and alerts to the use of the same insulin
pump with a flash glucose measurement (FGM) device not interacting with the pump.
Methods/design: Subjects meeting the inclusion criteria are randomized to treatment with the SAP or treatment
with an insulin pump and independent FGM for 5 weeks. Following a 3-week washout period, the subjects cross
over to the other study arm for 5 weeks. During the week before and in the last week of treatment, the subjects
and one of their caregivers wear a sleep monitor in order to obtain sleep data. The primary endpoint is the
between-arm difference in percentage of time in glucose target during the final 6 days of each treatment arm,
measured by a blinded continuous glucose measurement (CGM).
Additional endpoints include comparison of quantity and quality of sleep as well as quality of life perception of
the subjects and one of their caregivers in the two different treatment arms.
Recruitment started in February 2017. A total of 36 patients are planned to be randomized. The study recruitment was
completed in April 2018.
Discussion: With this study we will provide more information on whether insulin pump treatment combined with
more technology (SmartGuard® feature and alerts) leads to better metabolic control. The inclusion of indicators on
quality of sleep with less sleep interruption, less lack of sleep and perception of quality of life in both children and
their primary caregivers is essential for this study and might help to guide us to further treatment improvement.
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measurementType 1 diabetes Background
Patients with type 1 diabetes (T1D) need lifelong insulin
treatment and optimal metabolic control, which is es-
sential to prevent short- and long-term complications
[1]. To achieve optimal metabolic control, the day-to-day
management is challenging for the children and their fam-
ilies and can have a major negative impact on their quality
of life [2, 3].
Augmenting an insulin pump with glucose sensor
information leads to improved outcomes. Whilst continuous
interstitial glucose monitoring is associated with decreased
haemoglobin A1c (HbA1c) levels and reduced time spent in
hypoglycaemia in individuals with T1D using insulin pump
therapy, better outcomes are associated with longer and
continued use of the sensor [4]. Alerts are programmed and
used in sensor-augmented pumps (SAPs) in order to inform
patients and their caregivers about hypoglycaemic and
hyperglycaemic events so that they can react quickly to such
glycaemic excursions. However, alerts may be perceived as
disturbing and may lead to diabetes distress and alert fatigue
as well as continuous nocturnal awakenings [5].
Fear of nocturnal hypoglycaemia is common amongst
parents of children with T1D, and it is associated with
heightened vigilance by parents to regularly control their
children’s blood sugar values or to check the sensor infor-
mation during the night [6, 7]. This leads to chronic sleep
interruption and to lack of sleep for the parents as well as
for their children with diabetes [8]. Recent data show that
99% of parents of children with T1D perform blood glucose
checks on their child during the night to ensure their safety
whilst sleeping [9]. This highly prevalent chronic sleep
interruption affects both adults with T1D and parents/
carers of children with T1D, with resulting negative effects
on their daily functioning and well-being [10]. Anxiety and
fear of hypoglycaemia may have an impact on diabetes
management and may complicate meeting glucose targets
in patients with T1D [11, 12]. A recently published
multicentre evaluation shows that SmartGuard® technology
significantly reduced the risk for hypoglycaemia in paediatric
diabetes patients without increasing HbA1c [13].
The MiniMed 640G® pump combines alerts with an auto-
mated insulin suspension; the pump suspends insulin infu-
sion when the sensor glucose (SG) is within 3.9 mmol/l
(70 mg/dl) above the low limit and predicted to be
1.1 mmol/l (20 mg/dl) or lower above the low limit in
30 min. Suspension lasts for a minimum of 30 min and
until a 2-h suspension time is reached or the patientmanually resumes basal rate infusion or auto-resumption
occurs when the trend in glucose shifts and the SG is pre-
dicted to be 2.2 mmol/l (40 mg/dl) above the threshold in
30 min. Alerts can be set on or off; the low threshold alert
is mandatory (SmartGuard®).
FreeStyle Libre® is another device that continuously
measures the interstitial glucose levels. The results can
only be obtained when the patient/caregiver actively
scans the sensor (flash glucose measurement, FGM). No
alerts are given when glucose values increase or decrease,
nor will information be available when the sensor is not
scanned, and data are lost when more than 8 h elapse
between scans. No communication exists between this
glucose measurement and the insulin pump. The advan-
tage of the FGM is intermittent access to 24-h glucose
profiles without disturbing alerts.
Without any alerts, however, the symptoms of high
or low glucose levels may be missed, and intervention
delayed.
The impact of these technologies on metabolic control
has been studied before [14]. We are not aware of any
study evaluating their impact on quality of sleep in
children and their caregivers, using questionnaire and
Actigraph® data.Objective
The objective of this study is to evaluate whether the SAP
(MiniMed 640G®) with SmartGuard® feature increases
time in glucose target and improves sleep quality and
quantity and quality of life perception in patients with T1D
and their primary caregivers, when compared with pump
treatment with only continuous monitoring, FreeStyle
Libre®.Methods
Study design
In this open-label, single-centre, randomized two-period
crossover study, based in the Children’s Hospital in
Luxembourg, subjects with type 1 diabetes (6–14 years old,
diabetes duration more than 6 months, on insulin pump
for at least 6 months, HbA1c ≤ 11%) are randomized to
treatment with SAP with the SmartGuard® feature
(MiniMed® 640G) or treatment with insulin pump and
independent interstitial glucose measurement (FreeStyle
Libre®) for 5 weeks. Following a 3-week washout period,
the subjects cross over to the other study arm for 5 weeks.
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sleep monitor (Actigraph®) and complete a sleep diary the
week before and during the last week of each treatment.
This allows a comparison of the quality of sleep of the par-
ticipants as well as the parents between the two treatment
arms.
Randomization is performed by blocks of 8 with se-
quences A – B and B – A for the first and second periods
respectively. Allocation is based on envelopes where the
sequence code is concealed in advance. The order of the
envelopes is determined by the randomization order and
will allow allocation of the patient to one of the two
sequences.
Reporting standards will be ensured by a rigorous
quality process. The statistical process will include a
statistical analysis plan approved by all members of the
project team which will be applied for the statistical
analysis of the study. Programming of the statistical
analysis will be achieved and validated with a prelimin-
ary set of data and validated again when all data are
available. Reporting will be done by the project statisti-
cian in a statistical report and validated by a second
statistician.
The primary endpoint is the between-arm difference
in percentage of time in glucose target during the final
6 days of each treatment arm, measured by a blinded
continuous glucose measurement (CGM) (IPro2®).
Secondary endpoints include sleep duration, number of
awakenings during the night and information about state
of fatigue and activities in the daytime.Fig. 1 Timeline of QUEST studyBaseline and repeated assessment measures
Demographic variables are sex, age, income, education
and socio-economic status; anthropometric variables are
weight (kg) and height (m). Quality of life perception will
be assessed together with quality of sleep perception by
questionnaires evaluating income, current professional
activity, highest educational degree, hypoglycaemia fear,
sleepiness and potential family responsibility [15–19].
Procedures
After they have received general information on the
study aim and design, and also on the devices (pump,
SmartGuard®, FreeStyle Libre® and Actigraph®), the parents
and children who wish to participate in the study will be
invited for the first visit (V0). The study timeline is shown
in Fig. 1. The Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) schedule of interventions
and assessments is shown in Fig. 2. The consent form
(Additional file 1), trial questionnaires (Additional files 2, 3,
4 and 5), sleep diaries (Additional files 6, 7 and 8) and trial
information (Additional files 9, 10, 11, 12, 13 and 14), as
well as the populated SPIRIT checklist (Additional file 15).
At visit V0, after signing the informed consent/assent, the
patients will be randomized to one of the two sequences
(starting either with 640G with SmartGuard® or with FGM).
Patients and one parent will be invited to fill out the
questionnaires. A baseline HbA1c value and demo-
graphic and clinical data will be obtained in a case re-
port form (CRF). During this period, all patients will be
asked to perform a minimum of four capillary glucose
Enrolment Allocation Post-allocation
TIMEPOINT V0 V0 V1 V2 Wash-out V3 V4
ENROLMENT:
Eligibility screen X
Informed consent X
Information X
Allocation X
INTERVENTIONS:
Treatment A-B A A B B
Treatment B-A B B A A
ASSESSMENTS:
Actigraph/IPRO2
X X X X
CRF
X X X X
Questionnaires/
SleepDiaries
X X X X
Fig. 2 SPIRIT schedule of interventions and assessments
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pumps). No sensor (CGM or FGM) will be used during
this week. The patient and one caregiver will be pro-
vided with an Actigraph® and will be asked to fill out
the sleep diaries during the 7 days of wearing the
Actigraph®.
At the next visit (V1), the Actigraphs® will be collected
for analysis. All patients will be started on the MiniMed
Medtronic 640G pump, and either the SmartGuard® or
the FGM will be initiated.
As all patients are pump wearers, the transition to-
wards the Medtronic 640G pump is not complicated.
The use of the two glucose measurement tools will be
discussed during the dedicated training session. A 24/7
diabetes hotline will be accessible for technical or any
other issues.
Settings of the SmartGuard®are standardized based on
current experience [13]. The low limit will be set at
3.4 mmol/l (61 mg/dl) with an insulin suspension at
≤7.3 mmol/l (131 mg/dl) if the predicted value within
30 min is 4.5 mmol/l (81 mg/dl). An alert before low will be
set on to inform the parent/patient that insulin administra-
tion is suspended. It may take time for parents to developconfidence in the new technology; therefore, in this study,
we decided to include the alert before low.
At the next visit, V2 (after 4 weeks of treatment), the
patients and families will be invited to complete the
questionnaires. HbA1c values will be measured, and the
CRF will be completed. The IPro2® for blinded CGM will
be placed for 7 days, and the patient will be instructed
to perform two glucose measurements/day for calibration.
The Actigraphs® will be provided. Patients and parents will
be asked to fill out the sleep diaries during the following
week.
This week will be followed by a washout period of
3 weeks.
During this period, the 640G pump will be maintained,
but in combination with a minimum of four blood glucose
measurements and no CGM or FGM.
Sleep assessment will be conducted with Actigraphs®
and sleep diaries 1 week before the start of the second
treatment arm.
At visit V3, the second treatment period will be started
on either FGM or SmartGuard®.
At visit V4, after 4 weeks of the treatment arm, the CRF
and the questionnaires will be completed, the IPro2® for
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asked to perform two blood glucose measurements per
day. Actigraphs® are provided, and patients and parents
will be asked to fill out the sleep diaries.
After this week the devices will be collected for analysis,
and the patient will restart his/her pre-study treatment.
Ennov Clinical software will be used for data manage-
ment throughout the study. For the sleep analysis, Actilife®
software will be used.
Data management and data quality
Time in glucose target will be evaluated by the blinded
CGM at the end of both treatment arms.
Data will be extracted from the blinded CGM with the
Medtronic GlyVaRT software tool. The pump is uploaded
to transfer information to Medtronic CareLink therapy
management software through the use of a Contour Next
Link® glucose meter, which is also the uploading device.
Data quality will be ensured in the data management
process. Double data entry will be performed in specific
forms within Ennov Clinical, including online logical con-
trols. A confrontation of both databases will be regularly
carried out.
Statistical analysis
The percent time below glucose target, < 3.0 mmol/l
(54 mg/dl) and < 2.5 mmol/l (45 mg/dl), in glucose target
(3.9–8 mmol/l, 70.2–144 mg/dl) and above glucose target
(> 10 mmol/l, 180 mg/dl) during the final 6 days of a
5 week period will be compared between arms by using a
linear model with treatment, sequence of treatments and
period as fixed effects.
Sleep patterns will be assessed after sleep data validation
by examining each sleep pattern. First, we will validate if
the device was used a minimum of 5 days; second, we will
analyse wear time and finally we will correct the sleep
onset and morning wake-up according to data collected
by the sleep diary.
Total sleep and wake time and number of awakenings
at baseline, week 5 and week 13, in patients and at least
one of their caregivers, will be analysed by using a linear
mixed model with treatment given and period of treatment
as fixed effects factors and patient as a random effect. The
impact of family responsibility scale will be tested in the
model, as well as time in target, age, gender and socio-
economic status and daily physical activity.
Quality of life perception and quality of sleep (Epworth
Sleepiness Scale and sleep diary) in patients and in at
least one of their caregivers in the two treatment arms
at baseline, week 5 and week 13 will be analysed by
using a linear model or a model for categorical outcome
depending on the studied outcome.
The Hypoglycaemia Index for children and the
Hypoglycaemia Fear Survey for parents/caregivers atbaseline, week 5 and week 13 will also be analysed with
the model specific to crossover trials.
A comparison of sleep diary data versus Actigraph®
data will be carried out.
Severe hypoglycaemia, defined by the International Society
for Pediatric and Adolescent Diabetes (ISPAD) [12] will be
analysed through a table of frequencies.
Total sleep time will be analysed using a linear mixed
model with treatment given and period of treatment as
fixed effects factor and patient as a random effect. Sleep
analysis will be performed with Actilife® Software calculat-
ing duration of sleep during day and night and number of
awakenings, in comparison with the sleep diaries.
Sample size
Based on paediatric data, the percent time spent in glu-
cose target (3.9–8 mmol/l) in the paediatric population is
estimated to be 40–50%. Assuming that an increase of
10–15% in time in glucose target is considered as clinically
meaningful, a significance level set at 5% (two sided) and a
power of 80%, a minimum number of patients of 31 per
group would be necessary. Taking into account the
within-subject standard deviation and a maximum 10%
of dropouts, a sample size of 36 patients should be
included in the study.
Timeline/recruitment/checklist
Ethical approval for the final study was obtained in
January 2017. Recruitment started in February 2017.
The study was completed in April 2018. The timeline
of the study is shown in Fig. 1. A SPIRIT checklist for
this study protocol is included as Additional file 15.
Discussion
With this study we will provide more information on
whether insulin pump treatment combined with more
technology (SmartGuard® feature and alerts) leads to
better metabolic control. As diabetes is a chronic disease
and will require lifelong treatment, the impact of quality
of life and sleep may play a role in treatment adherence
and outcome. The inclusion of indicators on quality of
sleep with less sleep interruption, less lack of sleep and
perception of quality of life in both children and their
primary caregivers is essential for this study and might
help to guide us to further treatment improvement.
Trial status at time of manuscript re-submission in
October 2018
Patient recruitment has been completed.
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